Peptide library

What is the
“NAD peptide”?

NAD+ is not a peptide; it is a different kind of molecule. What it is, why FDA reviews it alongside some peptides, what human trials have measured, and where regulators stand in November 2026.

Short answerCompound research · 8 min read · Updated 18 Nov 2026

There is no NAD peptide: NAD+, nicotinamide adenine dinucleotide, is a coenzyme built from two nucleotides, with no amino acids. It is grouped with peptides through regulation, not chemistry: FDA reviews it in the same pharmacy-compounding process as several peptides, and lists NAD in Category 1, under evaluation (list updated 14 May 2026). Drugs@FDA lists no approved medicine containing it (November 2026).

Key takeaways

  • NAD+ (nicotinamide adenine dinucleotide; nonproprietary name nadide) is a coenzyme: two nucleotides joined through their phosphate groups. It has no amino acids and no peptide bonds, so it is not a peptide.
  • In cells it carries electrons in energy metabolism, cycling between NAD+ and NADH, and enzymes such as sirtuins, PARPs and CD38 use it up.
  • Cells make it from the amino acid tryptophan and from B vitamins (niacin and nicotinamide); NR and NMN are precursors that cells convert into it.
  • A 2021 review lists two open questions: whether restoring NAD+ in ageing humans is free of harm, and whether it improves their health. Its authors declare competing interests.
  • In the US, FDA lists NAD in Category 1 of its pharmacy-compounding list, substances under evaluation (May 2026): an enforcement position for licensed compounders, not an approval.

01NAD+ at a glance

The short version, dated 18 November 2026. Every line is sourced at the end of the page.

QuestionNAD+
What it isA coenzyme, a helper molecule many enzymes need: nicotinamide adenine dinucleotide, two nucleotides (one carrying adenine, one carrying nicotinamide) joined through their phosphate groups.
Is it a peptide?No. It contains no amino acids and no peptide bonds.
Formula and massC21H27N7O14P2, 663.4 g/mol, as PubChem gives them for nadide (CID 5892).
Other namesNadide, its international nonproprietary name. Also coenzyme I and diphosphopyridine nucleotide (DPN). NADH is its reduced form.
Where it comes fromCells make it from the amino acid tryptophan and from B vitamins (niacin and nicotinamide), and recycle it from nicotinamide.
Evidence tierChemistry and roles in cells: established biochemistry. Raising it: further along in rodents (T3) than in people, a 2021 review says. Human trials: small (T1); a 2026 pooled analysis of four found no significant difference from placebo in its main outcomes, and a rise in a kidney marker with NAD+.
United StatesDrugs@FDA lists no approved product containing it (18 Nov 2026). FDA’s 503A list (updated 14 May 2026) puts NAD and NADH in Category 1, under evaluation, and one salt form in Category 3. It is not on the 503A bulks list in 21 CFR 216.23.
European UnionThe EMA’s data lists no centrally authorised medicine containing it (data of 18 Nov 2026).
United KingdomThe emc medicines database returned no result for nadide or nicotinamide adenine dinucleotide (18 Nov 2026).
AustraliaNot named in the Poisons Standard October 2026, and not being named does not make it approved or permitted. We did not check the ARTG.
WADANot named on the 2026 or 2027 Prohibited List. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply.

02Why is NAD+ not a peptide?

A peptide is a short chain of amino acids joined by peptide bonds; a protein is a longer chain of the same units. More: what are peptides? and peptide vs protein vs amino acid.

NAD+ is built from different parts. The US National Library of Medicine’s subject index (MeSH) defines it as “a coenzyme composed of ribosylnicotinamide 5′-diphosphate coupled to adenosine 5′-phosphate by pyrophosphate linkage”. In plain terms: two nucleotides, joined through their phosphate groups. One carries the base adenine. The other carries nicotinamide, a form of vitamin B3. MeSH files NAD under coenzymes and adenine nucleotides, not under peptides. Its name says the same thing: a dinucleotide is two nucleotides.

The “+” matters. NAD+ is the oxidised form. MeSH describes NAD as an electron carrier that is “alternately oxidized (NAD+) and reduced (NADH)”. Cells switch it back and forth to move electrons through their metabolism.

03Why is NAD+ grouped with peptides?

Because of how it is regulated, not because of its chemistry.

The US compounding lists. Substances that pharmacies want to compound are nominated to FDA and sorted into categories. FDA’s list, updated 14 May 2026, places “Nicotinamide Adenine Dinucleotide (NAD)” in Category 1, bulk drug substances under evaluation. The same category holds a peptide, vasoactive intestinal peptide, and many substances that are not peptides, such as glutathione, coenzyme Q10 and melatonin. The list groups substances by the nomination process, not by the kind of molecule. Background: FDA’s compounding categories.

04What does NAD+ do in cells?

NAD+ is “a coenzyme for redox reactions”, the electron-transfer steps of metabolism, “making it central to energy metabolism”, according to a 2021 review in Nature Reviews Molecular Cell Biology. Some enzymes also use it up as a raw material: the review names sirtuins, CD38 and poly(ADP-ribose) polymerases (PARPs). Those reactions release nicotinamide, which cells recycle back into NAD+ through a salvage pathway.

How cells make it. Some cells, “mostly in the liver”, build NAD+ from the amino acid tryptophan. Cells can also make it from niacin (nicotinic acid), a B vitamin, and recycle it from nicotinamide (vitamin B3). Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors on the recycling route: cells turn NR into NMN, and NMN into NAD+. They are different molecules from NAD+ itself.

Age. The same review reports “a gradual decline in tissue and cellular NAD+ levels” with age “in multiple model organisms, including rodents and humans”. It also lists what is not yet known: how to restore NAD+ levels during ageing, “whether doing so is safe and whether NAD+ repletion will have beneficial effects in ageing humans”. Drawing on laboratory studies, it warns that precursor supplements such as NR and NMN “may come at the cost of long-term side effects, such as enhancing chronic inflammation and cancer development”. Its authors declare competing interests, including research funding from a company.

05How has NAD+ been studied in people?

Research on raising NAD+ is further along in rodents than in people. The 2021 review puts it plainly: “Studies in humans are less advanced.”

Precursor trials. The review describes numerous human trials of NAD+ “boosters”. It says trials of the precursors NR and NMN have evaluated pharmacokinetics (how the body absorbs and clears them) and toxicology in healthy volunteers, and that phase I trials of NR “have provided conflicting results”.

Trials of NAD+ and NR, pooled in 2026 (T1, small). A systematic review and meta-analysis published on 17 November 2026 pooled four randomised, placebo-controlled trials. They enrolled 387 adults with symptomatic heart failure who were on standard treatment, and tested NAD+ or nicotinamide riboside. The primary outcomes were heart-failure hospital admissions, deaths from any cause and left ventricular ejection fraction, the share of blood the heart pumps out with each beat. None differed significantly from placebo. Nor did measures of heart size and strain, NT-proBNP (a blood marker of heart strain) or ALT (a liver marker). Serum creatinine, a kidney marker, rose with NAD+ (two trials, 209 people). The authors wrote that the treatments “appeared generally well tolerated in the short term”, but that the creatinine rise “warrants further evaluation”. They declare no competing interests.

We describe designs and measures, and report null results in full. How we grade studies: evidence grades. Why we never state amounts: our policy.

06What have regulators said about NAD+?

United States. Drugs@FDA, searched through openFDA for “nadide” and “nicotinamide adenine dinucleotide”, returned no approved product on 18 November 2026. NAD is not on the 503A bulks list in 21 CFR 216.23 (eCFR version of 16 November 2026). FDA’s list of nominated substances, updated 14 May 2026, puts “Nicotinamide Adenine Dinucleotide (NAD)” and its reduced form, NADH, in Category 1, “Bulk Drug Substances Under Evaluation”. It puts one salt form in Category 3, “Bulk Drug Substances Nominated Without Adequate Support”. For Category 1, FDA’s January 2025 guidance says that until a final rule decides whether a substance goes on the list, FDA “does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding with it, “if all of the following circumstances are present”. That covers those three kinds of compounder only. It is not an approval.

European Union and United Kingdom. The EMA’s data on centrally authorised medicines (export of 18 November 2026) lists no medicine containing it. On the same day, the UK emc database returned no result for nadide or for nicotinamide adenine dinucleotide. That database does not cover every UK licence.

Australia. NAD+ is not named in the Poisons Standard October 2026, and not being named does not make it approved or permitted. We did not check the Australian Register of Therapeutic Goods. More: are peptides legal in Australia?

Sport. WADA’s 2026 Prohibited List and its 2027 List, in force from 1 January 2027, do not name NAD+, NAD or nadide. The List’s classes include substances it does not name, with examples given as “including, but not limited to”, and anti-doping organisations decide how they apply. Athletes should check with theirs. See peptides and anti-doping.

07What we don’t know about NAD+

  • Whether giving NAD+ changes any health outcome in people. The trials pooled in 2026 were small and found no significant difference from placebo in their main outcomes.
  • What the creatinine rise seen with NAD+ means. The meta-analysis authors said it “warrants further evaluation”.
  • Whether raising NAD+ in ageing people is free of harm, and whether it benefits their health. The 2021 review lists both as open questions.
  • What a vial labelled NAD+ contains. Only a lab report on that lot can show its identity and purity: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act (Categories 1 to 3). List updated 14 May 2026; read 18 Nov 2026. www.fda.gov/media/94155/download
  2. U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance for industry, January 2025 (docket FDA-2015-D-3517); read 18 Nov 2026. www.fda.gov/media/174456/download
  3. 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A. Code of Federal Regulations, eCFR version of 16 Nov 2026; read 18 Nov 2026. www.ecfr.gov/current/title-21/section-216.23
  4. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs searched 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  5. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, registered 30 Sep 2026; full text searched 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  6. Database searches run 18 Nov 2026: Drugs@FDA through openFDA (“nadide”, “nicotinamide adenine dinucleotide”: no match; control “semaglutide”: found); EMA medicines data export, timestamp 18 Nov 2026 (no match); emc (“nadide”, “nicotinamide adenine dinucleotide”: no results; control “somatropin”: results). Registry and database queries. open.fda.gov/apis/drug/drugsfda/
  7. National Library of Medicine. Medical Subject Headings: NAD (D009243), with its scope note and tree position under Coenzymes and Adenine Nucleotides; Niacin (D009525); Niacinamide (D009536, entry terms include vitamin B3). Read 18 Nov 2026. id.nlm.nih.gov/mesh/D009243.html
  8. PubChem. Nadide, CID 5892: formula, molecular weight and synonyms (including nicotinamide adenine dinucleotide, coenzyme I, diphosphopyridine nucleotide). Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/5892
  9. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol, 2021;22(2):119–141. PMID 33353981 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
  10. Hamzah KA, Kurmasha YH, Elshabrawi MN, et al. [Systematic review and meta-analysis of four randomised placebo-controlled trials of NAD+ or nicotinamide riboside.] Eur J Clin Pharmacol, 2026;82(12):295. PMID 43040090 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/43040090/

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is NAD+ a peptide?

No. NAD+ is a coenzyme made of two nucleotides joined through their phosphate groups. It has no amino acids, so it is neither a peptide nor a protein.

Why is NAD+ grouped with peptides if it is not one?

The grouping comes from regulation, not chemistry. In the US, FDA reviews it in the same pharmacy-compounding nomination process as several peptides; that list sorts substances by how they were nominated, not by the kind of molecule.

What are NR and NMN?

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors. Cells convert NR into NMN and NMN into NAD+; they are different molecules from NAD+ itself.

Is NAD+ FDA-approved?

Drugs@FDA lists no approved product containing it (searched 18 November 2026). FDA lists NAD in Category 1 of its 503A compounding list (updated 14 May 2026), substances under evaluation, which is not an approval.

Is NAD+ on WADA’s Prohibited List?

WADA’s 2026 and 2027 Lists do not name it. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply, so athletes should check with theirs.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page